The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Informa
Skip to Page Content

Full Deal Summary

Leo Pharma AS licensed exclusive worldwide development and commercialization rights (except in Korea) to JW Pharmaceutical Corp.'s preclinical atopic dermatitis candidate JW1601.

JWP gets $17mm up front, up to $385mm in development and sales milestones, plus up to a double-digit royalty on net sales outside Korea. JWP acquired a global license to JW1601 from C&C Research Laboratories (a 1992 JV between JW and Chugai Pharmaceutical) under a May 2017 deal. Sometime this year JWP anticipates an IND filing for the candidate, an oral H4R antagonist, which has demonstrated both anti-pruritic and anti-inflammatory effects in animal models. The deal boosts Leo's existing atopic dermatitis pipeline, which includes Phase III tralokinumab, an IL-13 antibody; topical pan-JAK inhibitor delgocitinib (Phase III); and LP0145, a Phase I IL-22 antibody.


+ Show All | – Hide All

Financials


Click a figure for comparable deals.

Overview
Potential Deal Value $402.00mm
Total Milestones (pre- and post-sales) $385.00mm
Transactions 1 of 2 (08/2018)
(Cash) $17.00mm
(Total) $17.00mm
Royalty 1%
Royalty 10%
Transactions 2 of 2
Funding Stage MS Pre & Post Tot.
MS Pre & Post Tot. (Cash) $385.00mm
MS Pre & Post Tot. (Total) $385.00mm

Deal Information


Click a keyword for comparable deals.

Deal Industry Pharmaceuticals
Specialty Pharmaceuticals
Deal Status Final
Deal Type Alliance
R+D and Marketing-Licensing
Includes Royalty or Profit Split Information
Latest Phase at Time of Deal Research
Preclinical

Product Information


Click a keyword for comparable deals.

Product 1 of 1
Product Type Pharmaceutical
Lab Code JW1601
JW601
Mechanism of Action Histamine H4 receptor antagonist
Highest Phase at Time of Deal Research
Preclinical
Product Therapeutic Area(s) of Focus Dermatology
Dermatitis
Eczema
Licenser Name JW Pharmaceutical Corp.
Clinical Developer Leo Pharma AS
Licensee Name Leo Pharma AS
Carveouts for Leo Pharma AS
Territories Licensed Worldwide (All) (Exclusive)
Territories Excluded Worldwide
Asia
Pacific Rim
North Korea
South Korea